Jeppesen, P B1; Pertkiewicz, M2; Forbes, A2; Pironi, L2; Gabe, S M2; Joly, F2; Messing, B2; Loth, S2; Youssef, N N2; Heinze, H2; Berghöfer, P2
1 Department of Gastroenterology, Abdominal Centre, Rigshospitalet, The Capital Region of Denmark2 unknown
Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.